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Introduction
Diabetes mellitus is a chronic illness that requires continuing 
medical care and ongoing patient self-management education [1]. 
About 382 million people worldwide have diabetes and its prevalence 
is expected to increase by more than 50% in the coming twenty years 
[2]. The associated healthcare costs exceeded USD 548 billion in 2013 
[2]. About 90% of the diabetes population suffers from type 2 diabetes. 
Persons at high risk of type 2 diabetes usually progress slowly from the 
onset to the actual diagnosis during a period of eight to twelve years 
without experiencing any specific symptoms [3]. High risk of type 2 
diabetes has been referred to as prediabetes in people with Impaired 
Fasting Glucose (IFG) and/ Or Impaired Glucose Tolerance (IGT) 
[1]. Reduction in hyperglycemia, hypertension, and cardiovascular 
risk factors in people with prediabetes and type 2 diabetes is believed 
to reduce the risk of future micro- and macrovascular complications 
[4]. Early detection of both conditions and patient support in self-
management of their risk factors should be of crucial importance for 
the public health care policies. 
Therapeutic patient education (also referred to as patient – or self-
management education in this article) is an integral part of treatment 
and is defined as a collaborative process through which people with 
or at risk of type 2 diabetes gain the knowledge and skills needed to 
modify behavior and better manage their diabetes risk factors [5,6]. 
Multiple systematic reviews concluded that patient education is 
effective in improving glycemic control in people with type 2 diabetes 
in the short term [7-9]. 
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Abstract
Objective: To update current evidence on the cost-effectiveness (CE) of therapeutic education in prediabetes 
and type 2 diabetes.
Research design and methods: A systematic review of economic evaluations of therapeutic education in 
prediabetes and type 2 diabetes, based on Randomized Controlled Trials (RCTs) and published in 2002 - 2014. The 
quality of the clinical evidence was appraised through the Cochrane Collaboration’s tool for assessing risk of bias. 
Economic studies were evaluated through the Consensus Health Economic Criteria List. The Incremental Cost-
Effectiveness Ratios (ICERs) of patient education in prediabetes and type 2 diabetes were compared.
Results: Out of 2031 identified publications, eight studies on prediabetes and nine on type 2 diabetes met the 
inclusion criteria. The level of the underlying clinical evidence was overall high in studies on prediabetes and varied 
in studies on type 2 diabetes. The mean ICER (95% CI) from the perspective of the healthcare system was €18,000 
per QALY (range from dominance to €49,700) in prediabetes and €29,700 (range from €9,100 to €50,300) per QALY 
in type 2 diabetes. General flaws in the economic evaluations were short time horizons, limited uncertainty analysis 
and a lack of transparency in the modeling methods. 
Conclusions: The number of economic evaluations of patient education in prediabetes and type 2 diabetes 
has been growing in the past years. Our review compares the health economic evidence on therapeutic education 
for both conditions. The findings suggest that offering therapeutic education already in prediabetes stage may be 
a better value for money than postponing it till after the diagnosis. More robust methodologies in health economic 
evaluations are essential in further evidence generation. 
In individuals with prediabetes, a reduction in the rate of 
conversion to type 2 diabetes after intensive lifestyle interventions was 
demonstrated in several well-conducted randomized controlled trials, 
with risk reduction of 51% to 58% compared to controls in the short 
term and sustained risk reduction of 34% to 43% over a follow-up period 
of between 7 and 20 years [10]. Reversion to normal glucose regulation, 
even if transient, is associated with a significantly reduced risk of future 
diabetes [11]. In the above-mentioned studies, patient education was 
the fundamental component of the lifestyle interventions, with the aim 
of persuading people about an evidence-based diet and physical activity 
management. 
Current health economic evidence on the topic is too limited to 
formulate unambiguous recommendations on reimbursement policies. 
Several reviews of the Cost-Effectiveness (CE) of patient education in 
people with type 2 diabetes have been undertaken, without generating 
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any clear conclusions, mostly due to scarcity of publications or the 
limited quality of the studies [12-15]. Most economic evaluations of 
educational and lifestyle interventions to prevent type 2 diabetes in 
people with IGT were based on the results of the Diabetes Prevention 
Program [16]. Application of different modeling techniques produced 
conflicting results: in general very cost-effective [17-19], but not cost-
effective in the study by Eddy et al. [20]. 
The objective of this review is to update the knowledge on CE of 
therapeutic educational programs for people with prediabetes and type 
2 diabetes. This study will be the first to compare the existing evidence 
on both conditions. 
Methods
Data sources and searches
To identify the relevant studies we searched the Medical Literature 
Analysis and Retrieval System Online (MEDLINE), Excerpta Medica 
(EMBASE), Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), the Cochrane library, the Centre for Reviews and Dissemination 
database (CRD), Econlit. The search strategy was based on the combination 
of the following terms and their proximate notions: 1) type 2 diabetes or 
prediabetes; 2) patient education (including tele-counseling); and 3) costs 
or economics or quality adjusted life years or modeling. 
Study selection
Criteria for inclusion in the review were a combination of the 
following study characteristics: 1) the study population are adults with 
diagnosed type 2 diabetes or prediabetes; 2) the intervention is any 
structural program whose purpose is to improve disease knowledge 
and self-management skills, performed by any type of caregiver, with 
the use of any supporting material or devices; 3) the comparator is usual 
care; 4) the economic evaluation is based on a Randomized Controlled 
Trial (RCT); 5) the health effects are measured as Quality-Adjusted Life 
Years Gained (QALYs) or Life Years Gained (LYs); 6) the Incremental 
Cost-Effectiveness Ratio (ICER) is reported unless the intervention 
is dominant or dominated ; and 7) the study was published between 
January 2002 and April 2014. 
Exclusion criteria were: 1) partial economic evaluation, i.e. no 
analysis of the incremental costs of the intervention in relation to the 
incremental treatment effects; 2) economic modeling studies based 
on systematic reviews or meta-analyses, - due to variability in the 
organization of behavioral interventions and their effectiveness; 3) 
educational intervention did not include a human interaction, e.g. print 
– or video material; 4) the study participants represent a particular 
subgroup of patients with type 2 diabetes or prediabetes potentially 
limiting the generalizability of the results; and 5) published before 
2002. Earlier publications were not expected to apply the established 
methodologies for cost-effectiveness analysis as demonstrated by the 
previous systematic reviews [13-15]. 
The study selection was performed by two reviewers independently 
(IO and GG) in three rounds: titles, abstracts, full text. To reduce the 
risk of omission, the studies were included in the following selection 
round if they were selected by at least one of the reviewers. In the last 
round – full text inclusion – the study supervisors assisted in reaching a 
consensus on the final selection of the studies. The inter-rater agreement 
was calculated by means of kappa statistics after each selection round. 
Data extraction and quality of evidence assessment 
After the final selection of the economic evaluations, the original 
clinical studies were retrieved. To assess the quality of the health 
economic evidence, we first evaluated the internal validity of the RCTs 
by using the Cochrane Collaboration’s tool for assessing risk of bias and 
then applied the GRADE methodology to rank the level of the clinical 
evidence. High, moderate, low or very low grade of evidence was 
assigned to the studies with downgrading each time when one of the 
following was suggested: 1) limitations in design and implementation 
based on each topic of the risk of bias analysis; 2) indirectness of 
evidence; 3) unexplained heterogeneity or inconsistency of results; 4) 
imprecision of results; and 5) high probability of publication bias [21]. 
IO and GG performed the assessment independently. 
To critically appraise the quality of the economic evaluations, the 
Consensus Health Economic Criteria List (CHEC) was used [22]. We 
have extended the CHEC with a brief guidance to support each value 
judgment based on recently published methodologies and one question, 
specifically applicable to the decision-analytic models [23-25]. The 
following data were extracted for each study: the target population, 
the type of intervention, the comparator and the effectiveness results 
observed in the original RCT; the analytic horizon and the study 
perspective; the health and economic consequences of the alternative 
treatments considered and methods to measure and value costs 
and health outcomes; the discounting methods; and the performed 
uncertainty analysis. For the modeling studies, the models’ structural 
assumptions and validation methods were extracted. Each question of 
CHEC was answered with “yes/rather yes”, “no/rather no”, or “unclear” 
and justified. IO and LP assessed the studies independently and agreed 
on the assessment results. 
Data Synthesis and Analysis 
We reported the review results by grouping the economic 
evaluations per target population, based on the cost-effectiveness of the 
education program – from most to least cost-effective. For each study, 
the target population, the type of intervention, and the effectiveness 
results are reported; and the analytic horizon and the study perspective 
are specified. If not clearly stated in the study, the perspective was 
assumed based on the types of costs included in the analysis and 
reported as “assumed”. ICERs were rounded up to hundreds. To make 
ICERs comparable across the studies we converted all currencies into 
Euros by using the average standardized exchange rate of 2012 [26]. If 
the cost valuation year was not explicitly mentioned, we have assumed 
it to be the year prior to the study publication. For the purpose of the 
descriptive statistics, interventions which were found cost-saving, were 
included into the ICER analysis with the ICER value equal to zero. We 
adopted the classification of CE applied by Li et al. [17] as established 
by convention: dominant, or cost-saving; or - depending on costs 
per QALY - very cost-effective (0< ICER ≤ €20,000); cost-effective 
(€20,000<ICER ≤ €40,000); marginally cost-effective (€40,000< ICER 
≤ €80,000); not cost-effective (> €80,000).
The methodological quality of the studies was summarized by using 
the Review Manager software. 
Results
Design and quality of the included studies
The search yielded 2031 publications. Seventeen studies met the 
inclusion criteria; eight of them evaluated CE of lifestyle interventions in 
prediabetes. The study selection process is depicted in Figure 1. Eleven 
studies were based on decision analytic models and considered a long-
term time horizon. All models with the exception of that used by Eddy 
et al. [20] were Markov state transitions models in which participants 
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in the metformin group compared to the placebo group at 2.8 years 
follow-up. The educational intervention was an intensive lifestyle-
modification program with the goals of at least a 7% weight loss and at 
least 150 minutes of physical activity per week offered in a curriculum 
of 16 individual lessons during the first 6 months and subsequent 
individual and group lessons, mostly on a monthly basis.
Six out of eight studies found intensive lifestyle interventions 
cost-saving or very cost-effective: Palmer et al. [27] used the results of 
DPP to analyze the CE in five countries - Australia, France, Germany, 
Switzerland and the UK, - by applying a simple three-state Markov 
move from and to defined health states within discrete time periods. 
Most studies on prediabetes included the healthcare system and the 
societal perspective. The societal perspective was not considered in any 
of the studies on type 2 diabetes. 
The level of clinical evidence from the original clinical trials was 
ranked high in 50% of the RCTs and was overall higher in studies on 
prediabetes. One study on prediabetes and three studies on type 2 
diabetes were within-trial economic evaluations with a time horizon of 
no more than 3 years and as such ignored the long-term consequences 
of the interventions with regard to health outcomes and the associated 
treatment costs. Most modeling studies failed to deliver a transparent 
presentation of the model structural assumptions and validation 
methods. None of the studies was exhaustive in the performance and 
presentation of the uncertainty analysis. The accuracy in identification, 
measurement and valuation of the costs and outcomes varied. Outcomes 
of the reporting and quality assessment of the economic evaluations 
based on CHEC are summarized in Figure 2. A detailed report on the 
methodological flaws of the RCTs and the economic evaluations is 
available upon author’s request.
Cost-effectiveness of the studied interventions 
The mean ICER (95% CI) from the perspective of the healthcare 
system was €18,000 per QALY gained (range from dominant to 
€49,700) in prediabetes and €29,700 (range from €9,100 to €50,300) in 
type 2 diabetes. The boxplots of ICERs are presented in Figure 3. 
Below, we give a brief description of each study by reporting results 
from the original RCT, the type of intervention, the analytic technique 
applied and the CE results. 
Prediabetes
From eight studies on prediabetes, four were based on the Diabetes 
Prevention Program (DPP) [16] and three on 10 years follow-up of 
DPP. DPP is a well conducted RCT which demonstrated 58% reduction 
in incidence of type 2 diabetes in the intensive lifestyle group and 31% 
2329 records identified 
through database 
searching
 
10 records identified 
through other sources 
2031 records left after 
removal of duplicates and 
screened on title match
 
807 records selected 
for abstract review 
kappa 0.56
 
1224 records excluded               
Reasons:                                                          
- not type 2 diabetes/prediabetes  (313)            
- specific type 2 diabetes  population (81)               
- not patient education (705)                            
- not economic evaluation (125)
 92 records selected for 
full-text analysis  
kappa 0.72
 
715 records excluded                  
Reasons:                                                          
- not type 2 diabetes/prediabetes (5)                 
- specific type 2 diabetes population (1)                
- not patient education  (109)                        
- not economic evaluation (600)
 17 records included 
into the review analysis
kappa 0.81
 
75 records excluded                     
Reasons:                                                          
- not patient education as defined above (11)              
- not based on RCT (30)                                  
- no ICER reporting (34) 
Figure 1: Selection of cost-effectiveness studies for systematic review of 
therapeutic education to prevent the development and progression of type 2 
diabetes.
Figure 2. Authors’ judgments about compliance with good practices in the 
included studies, for each item of the modified CHEC checklist.
Figure 3: Boxplots of the incremental cost-effectiveness ratios in Euros (2012) 
per QALY gained of patient education in prediabetes and type 2 diabetes from 
the perspective of the healthcare system. 
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model with the states IGT, alive with type 2 diabetes and deceased, over 
a lifetime horizon. The intervention was found to be cost-saving in all 
countries except in the UK, where it was very cost-effective with an 
ICER of €6400 per life-year gained.
Lindgren et al. [28] investigated lifelong CE based on the 
Finnish Diabetes Prevention Study [29,30]. This RCT of good quality 
demonstrated a 58% reduction in cumulative incidence of type 2 
diabetes at 6 years compared to controls. The intervention consisted 
of individual nutritionist advice on reduction in weight of at least 5%, 
total fat intake less than 30% and saturated fat intake less than 10%, fiber 
intake of 15 g/1000 kcal, and moderate exercise of at least 30 minutes per 
day. In addition, supervised individual resistance training to improve 
the strength of the large muscle groups was offered. In the long-term 
effect analysis, the transition states of the used model are limited to IGT, 
type 2 diabetes, myocardial infarction/ stroke and death. The lifestyle 
intervention was found to be cost-saving from the payers and the societal 
perspective with a maximal cost of €2400 per QALY gained.
Palmer et al. [31] projects lifetime clinical and economic outcomes 
based on the results from the DPP and a 10 years follow-up of DPP, 
Diabetes Prevention Program Outcomes Study (DPPOS), from a 
third-party payer perspective in Australia [32]. The model is similar 
to that applied in Palmer et al. [27] but adds one additional health 
state, - “normal glucose regulation” and thus accounts for reversion to 
normoglycemia. Intensive lifestyle intervention comes out as a cost-
saving intervention, metformin costs AUD10100 (€8100) per QALY.
Herman et al. [33] explored the CE of DPP through lifetime 
modeling. Probabilities of transition from IGT to diabetes onset, type 
2 diabetes, all known diabetes complications and death were included 
in the analysis based on an existing model, built mainly on data from 
the United Kingdom Prospective Diabetes Study (UKPDS). The ICER 
of the intensive lifestyle intervention was $1100 (€900) per QALY from 
the healthcare perspective and $ 8,800 (€6800) per QALY from the 
societal perspective [34]. 
“DPPRG, 10 years follow-up”, 2012, U.S. [35] is a within-trial CE 
analysis of DPPOS [36]. At 10 years, the incidence of diabetes was 
34% and 18% lower in the intensive lifestyle and the metformin group 
respectively if compared to the placebo group. After DPP, all groups 
were offered 16 lifestyle support group sessions during 7 months (DPP-
bridge). In the 5.7 subsequent years, all groups could participate in the 
Healthy Lifestyle Program (HELP) consisting of four quarterly one-
hour group visits. In addition, the original intensive lifestyle group 
was offered two group classes aimed at self-management behaviors for 
weight loss (BOOST). The metformin group continued with metformin. 
The attendance rate was 18% for HELP and 17% for BOOST. The ICER 
was $12900 (€10000) per QALY from the healthcare system perspective 
and $19800 (€15300) from the societal perspective. 
Herman et al. [36] is based on DPPRG, 10 years follow-up and is a 
post-hoc CE analysis for the subgroup of “adherent” patients. Adherent 
lifestyle participants were defined as those without diabetes who 
achieved and maintained 5% weight loss at ≥ 50% of their semi-annual 
visits; adherent metformin participants as those without diabetes who 
took ≥ 80% of their prescribed metformin; adherent placebo participants 
as all those randomized to the placebo group. The incidence of diabetes 
among “adherent” patients from the intensive lifestyle group at 10 years 
was 49.4% lower than in placebo and 20.8% lower than in metformin 
group. For the intensive lifestyle intervention, ICERs were $20,000 
(€15,500) and $3200 (€2500) per QALY from the healthcare and the 
societal perspective respectively. Metformin costs $20200 (€15,700) per 
QALY, from the healthcare system perspective, and is cost-saving from 
the societal perspective. In this study, the measure of adherence was the 
treatment effect in the intensive lifestyle group and the compliance to 
the intervention protocol in the metformin group, while in the placebo 
group all patients were considered adherent. The inconsistency in the 
definition of adherence across groups seems a substantial flaw of the 
study design and its results should be interpreted with caution. 
Marginal cost-effectiveness was found in the within-trial 
economic evaluation along DPP, which provides an accurate reporting 
of costs and outcomes within the RCT [37]. However, due to the short 
time horizon, it ignores all future consequences of the alternative 
treatments. The ICER of $51600 (€40,000) per QALY gained, calculated 
from the societal perspective, should therefore be interpreted with 
caution. Intensive lifestyle intervention was not cost-effective in the 
study of Eddy et al. [20] which explored the lifetime CE of DPP by using 
the Archimedes Diabetes model [38]. The model is based on object-
oriented programming and does not involve fixed health transition 
states. It consists of hundreds of variables that interact within hundreds 
of equations. The model was extensively validated and is described 
as highly precise. Eddy et al. conclude that delaying the lifestyle 
intervention until after a person develops diabetes would be more cost-
effective than offering it to people with IGT. The reported ICERs were 
$1,43,000 (€1,10,900) per QALY from the health plan’s perspective and 
$62,600 (€48,500) per QALY from the societal perspective. 
Type 2 diabetes
In type 2 diabetes, therapeutic education was found cost-saving 
only in the study of Mason et al. [39], and only for the subgroup of 
people with hypertension where the intervention was focused on blood 
pressure lowering strategies in the UK. It was very cost-effective in the 
same study for the subgroup of people with dyslipidemia with an ICER 
of $8230 (€6400) per QALY gained, supposedly from the health care 
perspective. The underlying RCT is of a good quality and demonstrates 
a significant increase of the percentage of patients at target for the 
level of total cholesterol (but not for the level of blood pressure) 
[40]. The specialist nurse-led intervention in this study was aimed 
at better control of hypertension and hyperlipidemia in diabetes and 
included individual target-driven lifestyle counselling and medication 
adjustment. The applied model includes the states: type 2 diabetes, 
myocardial infarction, stroke and death. 
Diabetes education was very cost-effective also in two other 
studies: Gillett et al. [41] investigated the lifetime CE of education 
for ongoing and newly diagnosed diabetics in the UK and found 
an ICER of £5387 (€6700) per QALY, from the healthcare system 
perspective. The one-year intervention was a structured 6-hours group 
education program focused on lifestyle and goal setting and delivered 
by professional health educators. There was no significant between-
group difference in effect on HbA1c, but there was a positive significant 
effect in odds of non-smoking [42]. The study used the Sheffield type 
2 diabetes models that include progression from diabetes without 
complications to micro- and macrovascular complications. 
Dijkstra et al. [43] analyzed the life-long CE of a diabetes passport 
– an intervention that included education sessions for patients and 
professionals in hospital setting [44]. Difference in HbA1c change after 
one year was 0.5% and statistically significant. The NIDDM model was 
used for the long-term extrapolation of results. Though the original 
clinical study reports a 2-arm design with a single complex intervention, 
ICERs of €16400 per QALY are reported for the patient-centric and 
€32200 per QALY for the provider-centric intervention. 
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Educational interventions in type 2 diabetes were cost-effective 
in three studies: Graves et al. [45] analyzed the CE of telephone 
counseling for physical activity and diet in primary care patients with 
type 2 diabetes or hypertension [46]. The RCT was of a good quality 
and demonstrated a significant improvement in intake of fat, vegetables, 
fruit and fiber achieved through 18 lifestyle telephone sessions offered 
by nutritionists. The model applies a 10-year time horizon and 
transition to different behavior states (suboptimal lifestyle – improved 
diet – improved exercise – improved diet and exercise) or death, each 
assigned a particular QALY value. The model is non-conventional as 
it uses health behaviors instead of health states. It is not clear how the 
evolution of the health status was incorporated into the model, nor how 
the transition probabilities and the associated health utility values were 
estimated beyond the trial. ICERs were AUD78500 (€63,300) per QALY 
compared to usual care and AUD29400 (€23,700) per QALY compared 
to “real controls”. 
Cleveringa et al. [47] investigated the life-long CE of the Diabetes 
Care Protocol, a complex one-year intervention that included patient 
education and medication prescription by nurses upon approval of 
GPs and with support of a computerized decision support system [48]. 
This well conducted RCT showed no significant difference in effect on 
HbA1c but did in the secondary outcomes – blood pressure and lipid 
profile. The model is based on Eastman’s Model of complications of 
Non-Insulin Dependent Diabetes Mellitus (NIDDM) adapted to the 
Dutch population and simulates progression to Cardiovascular Diseases 
(CVD) - angina pectoris and myocardial infarction, microvascular 
complications and death [49]. An ICER of €38200 per QALY from the 
health care perspective was reported. Although, the clinical trial did 
not include the subgroup analysis for people with and without CVD, 
the economic evaluation does report the results for these subgroups: 
for patients with CVD, the ICER was €14800, and for patients without 
CVD €121300 per QALY. 
The study of Handley et al. [50] is a within-trial economic 
evaluation of a nine-month education offered to patients with poorly 
controlled HbA1c. The intervention consisted of an automated 
telephone questionnaire and the outbound calls by nurse initiated when 
the answers are “out of range” [51]. Both the clinical and the economic 
evaluation contain some essential methodological flaws. The ICER 
ranged from $29402 to $72407 (€22800 - €56100) per QALY. 
A marginal cost-effectiveness of £43400 (€53600) per QALY 
gained was found in the study of Mason et al. [52] which explored 
the life-long CE of pro-active call center treatment support for people 
diagnosed with type 2 diabetes since more than one year in primary 
care [53]. The original well-conducted RCT demonstrates a statistically 
significant reduction of HbA1c after one year by 0.31%, achieved 
through outbound phone self-management support counselling with 
tailored intensity delivered by diabetes nurses. The long-term effects 
simulated in the model were not reported. Only a change in HbA1c was 
considered a risk factor of the disease progression. 
Educational support was not cost-effective in the study of Irvine 
et al. [54] which combines the effectiveness and the health economic 
analysis in one publication and investigates the CE of group education 
for people with IGT and newly diagnosed type 2 diabetes. The study 
has many methodological limitations. The reported ICER is £67174 
(€82900) per QALY. More favorable results were found for the 
subgroups of people with IFG and those with a follow-up time longer 
than 4 months: £20620 (€25500) and £17075 (€21000) per QALY 
respectively. 
The study of Simon et al. [55] is a within-trial economic evaluation. 
It was based on a 3-arm RCT in which usual care was compared to 
the Self-Monitoring of Blood Glucose (SMBG) and to the SMBG along 
with coaching for people with non-insulin treated type 2 diabetes [56]. 
The study reports low adherence rates: only 54 out of 151 people are 
adherent to the intensive SMBG; only 85 out of 150 – in the normal 
SMBG. No significant improvement in glycaemic control was found 
after one year. In both intervention groups, a non-significant loss in 
QALYs was observed. SMBG was evidently found to be dominated by 
usual care. 
Discussion 
The main finding of our review is that that therapeutic education 
may be a good value for money in patients with pre-diabetes and type 
2 diabetes. Current evidence suggests that offering education programs 
already in prediabetes stage would be a better strategy than postponing 
them till after the diagnosis. 
Six out of eight studies on prediabetes found patient education cost-
saving or very cost-effective. Other two studies reported less favorable 
results. One of them considered only a short-term analytic horizon. The 
meaningfulness of short-term cost-effectiveness analysis of therapeutic 
education in type 2 diabetes is questionable. As confirmed by 10 years 
within-trial analysis of DPP, the greatest costs are observed in the year 
of the delivery and decreased in the subsequent years, while most of the 
benefits occurred after 3 years of follow-up [35]. 
The other study was a modeling study by Eddy et al. [38] which 
concluded that intensive lifestyle interventions are not cost-effective 
with an ICER of €110900 per QALY gained. Five other modeling studies 
predicted such interventions to be cost-saving or very cost-effective 
with a maximum ICER of €6400 per QALY gained. The discussion on 
the predictive accuracy of different models stayed unresolved in absence 
of real life data. Only after the recent publication of the 10-years within-
trial CE analysis of DPPOS that calculated an ICER of €10000 per 
QALY, it becomes clear that the study by Eddy et al. produced results 
least consistent with the real life observations. This may be explained by 
adoption of a number of specific structural model assumptions, such 
as that the intervention would last for life, or that people with type 2 
diabetes who achieve HbA1c below 7%, stay well-controlled for the rest 
of their life.
In type 2 diabetes, the results were mixed and varied from cost-
saving to not cost-effective, or even dominated. Three out of nine 
studies were within-trial economic evaluations and thus considered 
only a short-term analytic horizon. None of the studies on type 2 
diabetes included a long-term analysis of costs and outcomes based 
on real life data. The quality of the underlying clinical evidence was 
overall stronger in studies on prediabetes. Thus, our review suggests 
that patient education in prediabetes stage is more cost-effective and 
supported by stronger evidence. 
The following relativizing thoughts should help to better 
interpret the results of the review
The health economic evaluations are generally performed when 
interventions are clinically effective. This review should thus not be 
used to draw conclusions on the clinical effectiveness of therapeutic 
education, but on the cost-effectiveness of interventions with a positive 
health effect, to support the policy makers and health professionals in 
their decisions.
Most economic evaluations in prediabetes were based on the results 
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of the Diabetes Prevention Program. In studies on type 2 diabetes, the 
quality of the clinical evidence varied. More research on the topic is 
needed, preferably performed in real-life settings, with special attention 
to the barriers and facilitators of successful changes in clinical practice. 
In the future, it will be important to identify subgroups where 
therapeutic education is expected to be more effective. The extent of beta-
cell dysfunction might, for instance, independently affect the disease 
progression. The 5.8-year follow-up of DPP showed that participants 
of the intensive lifestyle arm, who did not return to normoglycemia at 
least once during the trial, had a higher risk of progression to diabetes 
than the control group [11]. A risk reduction of 56% was found in those 
who returned to normal glucose regulation irrespective of the previous 
allocation to the intensive lifestyle or metformin arm [11].
The overall challenge of reviews in health economics is that 
inconsistencies in the conduct and reporting of the cost-effectiveness 
studies complicate a systematic comparison of the results, particularly 
when different time horizons are chosen, different modeling methods 
applied and the uncertainty around the structure, its parameters and 
the methodology is not sufficiently explored. Commonly accepted 
methodologies to perform and assess economic evaluations would lead 
to a generation of higher quality health economic evidence. 
One should be cautious with the generalization of the cost-
effectiveness results or their transfer to other settings. Next to potential 
differences in clinical effect – e.g. due to divergences in the organization 
of usual care, differences in the absolute and relative cost consequences 
may occur. The cost-effectiveness classification adopted in our review is 
conditional and does not necessarily reflect the national reimbursement 
policies. It is known that applying an explicit ICER threshold is 
not typical for the reimbursement policies in most countries [57]. 
Moreover, in general, cost-effectiveness is not the only criterion in 
the reimbursement decisions. Severity of disease, size of the target 
population, budget impact, and availability of the treatment alternatives 
may play a role next to legal, ethical and organizational issues. 
While keeping in mind these limitations to the synthesis and 
generalizability of results, our review suggests that re-consideration of 
public health priorities in the direction of earlier prevention of diabetes 
might be appropriate. This would imply more efficient screening 
methods for detecting people with prediabetes. Targeting people at 
high risk, such as hypertensive and obese patients, is believed to be 
cost-effective [58]. More insights into the evolution of blood glucose 
levels are needed to come up with an optimal re-test frequency. 
Conclusion
Therapeutic education may be cost-effective in prediabetes and 
type 2 diabetes, but offers a better value for money when offered in 
prediabetes stage. 
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